The Platform Group's AEP Puzzle: Can Management Convince Investors the Numbers Add Up?

After a 11.88% jump to €2.92, The Platform Group faces a credibility test: finalizing AEP acquisition financing before May-end. Pro-forma revenue could double, yet shares trade far below highs.

The Platform Group's management team is in Frankfurt today pitching to institutional investors at the Equity Forum spring conference, but the message they deliver will matter far more than the venue. The stock has clawed back to €2.92, jumping 11.88% from Friday’s close of €2.61 — a welcome reprieve after weeks of pressure. Yet the shares remain 8.87% below their 50-day moving average and a staggering distance from the year’s high of €5.50. The disconnect between operational momentum and market scepticism has rarely been wider.

At the heart of the conversation is the planned acquisition of AEP GmbH, a deal that would transform the company’s scale and shift its centre of gravity towards pharmaceuticals. The Federal Cartel Office cleared the transaction on 31 March 2026, and management expects to close by the end of May. The financing structure — a mix of equity and debt with maturities of three to five years — is still being finalised and will be communicated before the end of May. That timeline puts the next few weeks squarely in the spotlight.

The pro-forma numbers illustrate the potential step change. Without AEP, The Platform Group guides for a gross merchandise volume of €1.7 billion and net revenue of €1.0 billion in 2026, with adjusted EBITDA between €70 million and €80 million. With AEP included, pro-forma net revenue jumps to €2.0 billion, GMV to €3.2 billion, and adjusted EBITDA to €90 million–€100 million. The existing trading segment would be rebranded “Pharma & Service Goods” and would alone contribute more than €1.1 billion in pro-forma revenue.

Operationally, the company has been delivering. For the 2025 financial year, GMV rose 44% to €1.303 billion, adjusted EBITDA reached €55.0 million, and operating cash flow came in at €59.7 million — comfortably above the earnings figure. The 2026 targets without AEP are essentially an extension of that trajectory. Yet the stock has failed to reflect the progress. The current €2.92 price tag represents a deep discount to the book value implied by recent performance, and management knows that only clear, credible financing details can bridge the gap.

Investors will have two key milestones to watch. The quarterly report for the period ended 31 March is due on 27 May, followed by the annual general meeting in Düsseldorf on 1 July. By the time the first-quarter numbers land, the market will expect not just a clean set of operating figures but also concrete terms for the AEP financing. If management can present a structure that avoids excessive dilution or balance-sheet strain, today’s bounce could gain a foundation. If not, the gap between a growing business and a weak stock will only become harder to explain.

The roadshow in Frankfurt is more than a routine presentation. CEO and CFO are holding one-on-one meetings to explain the “Vision 2030” strategy and the scalability of their software platform — but the immediate credibility test is the AEP deal. The stock’s recent recovery from its lows shows that some buyers are willing to give the company the benefit of the doubt. Now the management has to prove that the pro-forma numbers are not just a paper exercise.